F-18-fluorodeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan;PET con 18FDG en pacientes con cáncer diferenciado de tiroides que presentan niveles elevados de tiroglobulina sérica y rastreos con 131I negativos

Revista Espanola de Medicina Nuclear

Volumn 24, Issue 1, 2005, Pages 5-13

  Ruiz Franco Baux, J V ^a   Borrego Dorado, I ^a   Gomez Camarero P ^a   Rodriguez Rodriguez J R ^a   Vazquez Albertino R J ^a   Navarro Gonzalez E ^a   Astorga Jimenez R ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Fluorine 18 fluorodeoxyglucose; Positron emission tomography; Radiolodine; Thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOACTIVE IODINE; THYROTROPIN; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; THYROGLOBULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PAPILLOMA; POSITRON EMISSION TOMOGRAPHY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; WHOLE BODY SCINTISCANNING; BLOOD; LABORATORY DIAGNOSIS; MIDDLE AGED; RETROSPECTIVE STUDY; SCINTISCANNING; THYROID TUMOR; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FALSE NEGATIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 14644408779     PISSN: 02126982     EISSN: None     Source Type: Journal    
DOI: 10.1157/13070351     Document Type: Article

References (25)

1. Lubin E, Mechlis-Frisch S, Zatz S, Shimini A, Segal K, Avraham A, et al. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastasic differentiated thyroid carcinoma. J Nucl Med 1994;35:257-62.
2. Galloway RJ, Smallridge RC. Imaging in thyroid cancer. Endocrinol Metab Clin North Am 1996;25:93-113.
3. Carreras JL, Lapeñ, Asensio C, eds. PET en Oncologfa. Madrid: Nova Sidonia Oncología-Hematología; 2002.
4. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987;28:910-4.
5. Sisson JC, Ackermann RJ, Meyer MA, Wahl RL. Uptake of 18F-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J. Clin Endocrinol Metab 1993;77:1090-4.
6. Feine U, Lietzenmayer R, Hanke J-P, Held J, Wöhrle H, Müller-Schauenburg W. Fluorine-18-FDG and iodine-131 uptake in thyroid cancer. J Nucl Med 1996;37:1468-72.
7. Grünwald F, Schomburg A, Bender H, Klemm E, Menzel C, Bultmann T, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996;23:312-9.
8. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997;24:1342-8.
9. Grünwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-52.
10. 18F)-2-fluoro-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999;84:2291-302.
11. Muros MA, Llamas-Elvira JM, Ramírez-Navarro A, Gómez MJ, Rodríguez-Fernández MJ, Muros T, et al. Utility of flurine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Am J Surg 2000;179:457-61.
12. 131I-negative papillary thyroid carcinoma. J Nucl Med 2000;41:1010-5.
13. 131I Scanning Results After Therapy. J Nucl Med 2001;42:1464-9.
14. 131I scan. J Nucl Med 2001;42:71-6.
15. Khan N, Oriuchi N, Higuchi T, Zhang H, Endo K. PET in the follow-up of differentiated thyroid cancer. Br J Radiol 2003;76:690-5.
16. 18F-Fluorodeoxyglucose Positron Emission Tomography in the Follow-Up of papillary or Follicular Thyroid Cancer. J Clin Endocrinol Metab 2001;86:3779-86.
17. McDougall IR, Davidson J, Segall GM. Positron emission tomography of the thyroid, with an emphasis on thyroid cancer. Nucl Med Commun 2001;22:485-92.
18. Sanders LE, Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 1998;133:419-25.
19. Spencer CA, Chen Wang CC. Thyroglobulin measurement, techniques, clinical benefits and pitfalls. Endocrinol Metab Clin North Am 1995;24:841-63.
20. Mazzaferri EL, Robbins RJ, Spencer CA, Braveman LE, Pacini F, Wartofsky L, et al. A Consensus Report of the Role of Serum Thyroglobulin as a Monitoring Method for Low-Risk Patients with Papillary Thyroid Carcinoma. J Clin Endrocrinol Metab 2003;88:1433-41.
21. Dadparvar S, Krishna L, Brady LW, Slizofski WJ, Brown SJ, Chevres A, et al. The role of iodine-131 and thallium-201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma. Cancer 1993;71:3767-73.
22. Galloway RJ, Smallridge RC. Imaging in thyroid cancer. Endocrinol Metab Clin North Am 1996;25:93-113.
23. 131I imaging in the follow-up of patients with well differentiated thyroid carcinoma. Nucl Med Commun 1996;17:373-7.
24. Carril JM, Quirce R, Serrano J, Banzo I, Jiménez-Bonilla JF, Tabuenca O, et al. Total-body scintigraphy with thallium-201 and iodine-131 in the follow-up of differentiated thyroid cancer. J Nucl Med 1997;38:686-92.
25. Grünwald F, Menzel C, Bender H, Palmedo H, Willkomm, Ruhlmann J, et al. Comparison of 18FDG-PET with 131 iodine and 99mTc-Sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997;7:327-35.